Jump to ContentJump to Main Navigation
Show Summary Details

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

IMPACT FACTOR 2015: 0.742

SCImago Journal Rank (SJR) 2015: 0.204
Source Normalized Impact per Paper (SNIP) 2015: 0.333
Impact per Publication (IPP) 2015: 0.507

Open Access
See all formats and pricing


Select Volume and Issue


Prognostic Value of High-Sensitivity C-Reactive Protein and Lipoprotein (a) in Acute Myocardial Infarction Patients Receiving Emergency Percutaneous Coronary Intervention

Shifang Ding1 / Yi Peng1 / Zhinan Chen1 / Juquan Jiang1 / Zhigang Gong1 / Zhigang Li1 / Qing Lu1 / Renxue Wang1

Department of Cardiology, Wuhan General Hospital, Guangzhou Military Command, PLA, Wuhan, 430070, China1

This content is open access.

Citation Information: Journal of Medical Biochemistry. Volume 31, Issue 2, Pages 131–134, ISSN (Online) 1452-8266, ISSN (Print) 1452-8258, DOI: 10.2478/v10011-011-0051-1, December 2011

Publication History

Published Online:

Prognostic Value of High-Sensitivity C-Reactive Protein and Lipoprotein (a) in Acute Myocardial Infarction Patients Receiving Emergency Percutaneous Coronary Intervention

In order to study the prognostic value of high-sensitivity C-reactive protein (hsCRP) and lipoprotein (a) [Lp(a)] in patients receiving emergency percutaneous coronary intervention (PCI) following acute myocardial infarction (AMI), we retrospectively reviewed 118 patients who received emergency PCI following AMI from January 2007 to April 2010. The plasma levels of hsCRP and Lp(a) were determined. The incidence of cardiovascular events was compared between patients with an elevated hsCRP level and those with a normal hsCRP level and between patients with an elevated Lp(a) level and those with a normal Lp(a) level. Results showed that the incidence of cardiovascular events was 52.9% in the hsCRP-elevated group and 18.2% in the hsCRP-normal group displaying a significant difference (P=0.011). However, the incidence of cardiovascular events was 35.3% in the Lp(a)-elevated group and 46.4% in the Lp(a)-normal group and statistical analysis revealed no significant difference (P=0.733). HsCRP, but not Lp(a), can serve as a prognostic factor for patients receiving emergency PCI following AMI.

Prognostička Vrednost Visokoosetljivog C-Reaktivnog Proteina i Lipoproteina (a) Kod Pacijenata sa Akutnim Infarktom Miokarda Podvrgnutih Hitnoj Perkutanoj Koronarnoj Intervenciji

Kako bi se utvrdila prognostička vrednost visokoosetljivog C-reaktivnog proteina (hsCRP) i lipoproteina (a) [Lp(a)] kod pacijenata podvrgnutih hitnoj perkutanoj koronarnoj intervenciji (PKI) posle akutnog infarkta miokarda (AIM), retrospektivno je analizirano 118 pacijenata podvrgnutih hitnoj PKI posle AIM između januara 2007. i aprila 2010. Određeni su nivoi hsCRP i Lp(a) u plazmi. Upoređena je incidenca kardiovaskularnih događaja kod pacijenata sa povišenim nivoom hsCRP i onih sa normalnim nivoom hsCRP, kao i između pacijenata sa povišenim nivoom Lp(a) i onih sa normalnim nivoom Lp(a). Rezultati su pokazali da je incidenca kardiovaskularnih događaja bila 52,9% u grupi sa povišenim hsCRP i 18,2% u grupi sa normalnim hsCRP, što je ukazalo na značajnu razliku (P=0,011). Međutim, incidenca kardiovaskularnih događaja bila je 35,3% u grupi sa povišenim Lp(a) i 46,4% u grupi sa normalnim Lp(a), a statistička analiza nije otkrila značajnu razliku (P=0,733). HsCRP, ali ne i Lp(a), može poslužiti kao prognostički faktor kod pacijenata podvrgnutih hitnoj PKI posle AIM.

Keywords: high-sensitivity C-reactive protein; lipoprotein (a); acute myocardial infarction; emergency percutaneous coronary intervention; prognosis

Keywords: visokoosetljivi C-reaktivni protein; lipoprotein (a); akutni infarkt miokarda; hitna perkutana koronarna intervencija; prognoza

  • Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006; 27: 779-88.

  • Le May MR, So DY, Dionne R, Glover CA, Froeschl MP, Wells GA, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2008; 358: 231-40.

  • Kones R. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Therapeutic Advances in Cardiovascular Disease 2009; 3: 309-15.

  • Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331-9.

  • Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.

  • Petrović D, Obrenović R, Trbojević-Stanković J, Majkić-Singh N, Stojimirović B. Cardiovascular Mortality in Hemodialysis Patients: Clinical and Epidemiological Analysis. Journal of Medical Biochemistry 2011; 30 (4): 302-8. [Web of Science]

  • Shen J, Ordovas JM. Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents. Clin Chem 2009; 55: 256-644.

  • Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, et al. Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur Heart J 2008; 29(10): 1241-9. [PubMed]

Comments (0)

Please log in or register to comment.